



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release
December 15, 2020

Financial Calendar 2021

Curasight A/S (Ticker: CURAS, CURAS T01) today announces that the company expects to publish financial reports according to the following schedule:

Deadline for submission of shareholder proposals to Annual General Meeting
February 11, 2021

Annual Report 2020 and Interim Report Q4 2020 (previously announced February 20, 2021)
February 24, 2021

Annual General Meeting 2021
March 25, 2021

Interim Report Q1 2021
May 20, 2021

Interim Report First Half 2021
August 24, 2021

The financial reports will upon their release be available at the Company's website, www.curasight.com, where information relating to Curasight's Annual General Meeting 2021 will also be available in due course prior to the meeting.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.